STOCKWATCH: Name, Platform; Time of death, December 2013
This article was originally published in Scrip
They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around their portfolios to off-load risk and negative cash flows onto the public markets from investments that weren't formed five minutes ago, then we see the platform companies.
You may also be interested in...
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.
GLP-1 agonists are creating a stir in obesity management and could possibly prevent non-alcoholic fatty liver disease, with implications for developers of NAFLD treatments. Similarly, another preventative intervention might succeed the treatments for Alzheimer’s disease.